Infectious Disease

Moderna seeks EUA for fourth dose of COVID-19 vaccine for all adults

March 18, 2022

1 min read

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . ” data-action=”subscribe”> Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Back to Healio

Moderna announced that it is seeking an emergency use authorization from the FDA for an additional booster dose of its COVID-19 vaccine for all adults.

The company applied for the EUA for anyone aged 18 years or older who has already received a booster dose of any authorized COVID-19 vaccine.

Source: Adobe Stock

Moderna announced that it is seeking an emergency use authorization from the FDA for an additional booster dose of its COVID-19 vaccine for all adults. Source: Adobe Stock.

The submission was based partly on data from Israel and the United States following the emergence of the omicron variant that demonstrated the benefits of an additional dose of the vaccine, according to a press release.

The company did not specify what the data showed, but a recently published study in The New England Journal of Medicine that assessed a fourth dose of either the Pfizer-BioNTech or Moderna messenger RNA vaccine among health care workers showed it was safe and boosted antibody levels similarly to levels observed after a third dose. Although the trial is ongoing, researchers noted that, so far, a fourth dose did not appear any more effective at preventing infection with the omicron variant.

If approved, the EUA for Moderna’s vaccine would be broader than the one requested by Pfizer and BioNTech this week, which seeks authorization of a fourth dose for adults aged 65 years or older.

Moderna said the broader request would “provide flexibility” to the CDC and health care workers to determine the “appropriate use” for populations at higher risk of COVID-19 because of age or comorbidities.

References:

Regev-Yochay G, et al. N Engl J Med. 2022;doi:10.1056/NEJMc2202542.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . ” data-action=”subscribe”> Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles